Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | APEX1 | P27695 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543370 | 0.90 | POLB (0.35) | POLBTDP1L3MBTL1APEX1RECQL | |
| SCHEMBL2386798 | 0.83 | ALDH1A1 (0.50) | POLBTDP1L3MBTL1RECQLKMT2A | |
| SCHEMBL14338369 | 0.83 | ALDH1A1 (0.50) | POLBTDP1L3MBTL1RECQLKMT2A | |
| SCHEMBL6125172 | 0.83 | ALDH1A1 (0.50) | POLBTDP1L3MBTL1RECQLKMT2A | |
| SCHEMBL20561319 | 0.77 | POLB (0.45) | POLBTDP1L3MBTL1APEX1RECQL | |
| SCHEMBL20969078 | 0.74 | ALDH1A1 (0.32) | TDP1ALDH1A1 | |
| SCHEMBL20969195 | 0.74 | ALDH1A1 (0.32) | TDP1ALDH1A1 | |
| SCHEMBL449523 | 0.72 | POLB (0.42) | POLBTDP1L3MBTL1APEX1RECQL | |
| SCHEMBL431044 | 0.72 | POLB (0.42) | POLBTDP1L3MBTL1APEX1RECQL | |
| SCHEMBL23004976 | 0.71 | POLB (0.34) | POLBTDP1L3MBTL1APEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042788-B2 | Strongly Lewis acidic metal-organic frameworks for continuous flow catalysis | THE UNIVERSITY OF CHICAGO (US) | 2024-07-23 | — | — | US | disclosed |
| US-20210053042-A1 | STRONGLY LEWIS ACIDIC METAL-ORGANIC FRAMEWORKS FOR CONTINUOUS FLOW CATALYSIS | NATIONAL SCIENCE FOUNDATION | 2021-02-25 | — | — | US | disclosed |
| US-20210053042-A1 | STRONGLY LEWIS ACIDIC METAL-ORGANIC FRAMEWORKS FOR CONTINUOUS FLOW CATALYSIS | NATIONAL SCIENCE FOUNDATION | 2021-02-25 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-9309231-B2 | Bridged ring compounds as hepatitis C virus (HCV) inhibitors and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
| US-7662750-B2 | Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-02-16 | — | — | US | disclosed |
| US-20050153366-A1 | Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-07-14 | — | — | US | disclosed |
| US-5422365-A | Hydroxy, ether, and/or acyloxy substituted, saturated or partially unsaturated naphthalenes; for controlling insulin secretion | ADIR ET COMPAGNIE (FR) | 1995-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153366-A1 | Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds | RIPK4, RIPK2, ATRIP | POLB 4734/4885TDP1 3151/4885L3MBTL1 2891/4885 |
| US-12042788-B2 | Strongly Lewis acidic metal-organic frameworks for continuous flow catalysis | CD69, TECR, MCM4 | POLB 1804/4885TDP1 4823/4885L3MBTL1 1716/4885 |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | POLB 3291/4885TDP1 2859/4885L3MBTL1 3412/4885 |
| US-20210053042-A1 | STRONGLY LEWIS ACIDIC METAL-ORGANIC FRAMEWORKS FOR CONTINUOUS FLOW CATALYSIS | CD69, TECR, MCM4 | POLB 1804/4885TDP1 4823/4885L3MBTL1 1716/4885 |
| US-20150079028-A1 | Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof | SLC10A1, HAVCR2, UGT1A3 | POLB 1561/4885TDP1 3830/4885L3MBTL1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.